Translating Mechanistic Insights into Precision Therapeutics
CELLTIUM develops precision therapeutics for CMT1A and related neurological disorders by linking disease biology directly to phenotypic drug discovery. Powered by its proprietary PRECISION™ platform, the company is building a pipeline of targeted small-molecule programs.
Precision CMT1A Pipeline
CMT1A is driven by PMP22 gene dosage, resulting in Schwann cell and myelin dysfunction. CELLTIUM’s programs are designed to address core disease biology and preserve or restore peripheral nerve function.
Using disease-relevant discovery models, CELLTIUM identifies compounds intended to restore myelination and peripheral nerve function by addressing key features of CMT1A pathology. Its lead program, CTM26, has demonstrated preclinical activity in severe CMT1A mouse models. Follow-on programs with distinct mechanisms are expanding the pipeline.
PRECISION™ Platform
PRECISION™ is CELLTIUM’s proprietary neuro-phenomic discovery engine, integrating neurological disease models, high-content phenotypic screening, and AI/ML-driven multimodal analytics. By linking disease biology directly to phenotypic outcomes, the platform accelerates target identification, candidate prioritization, and lead optimization.
Advancing Toward the Clinic
CELLTIUM’s lead CMT1A program, CTM26, is progressing through IND-enabling studies to support future regulatory submissions and clinical development.